Who
Jennifer Riley
Chief Strategy Officer
Company insider
Files Form 4 as: Chief Strategy Officer, Avalo Therapeutics.
In numbers
- Trades disclosed
- 10
- Buys
- 0
- Sells
- 1
- Bought
- $0
- Sold
- $104K
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 1 Jan 2025
- Last trade
- 11 Aug 2026
- Last filed
- 12 Aug 2026
Companies traded
Activity over time
1 Aug – 1 Oct
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 11 Aug 2026filed 12 Aug 2026 | AVTX Avalo TherapeuticsBiotechnology | SEC FORM 4 Sold | $52K2,655 at $19.59 | filing |
| 11 Aug 2026filed 12 Aug 2026 | AVTX Avalo TherapeuticsBiotechnology | SEC FORM 4 Sold | $52K2,655 at $19.59 | filing |
| 10 Jun 2026filed 12 Jun 2026 | AVTX Avalo TherapeuticsBiotechnology | SEC FORM 4 Code F | $7,703588 at $13.10 | filing |
| 10 Jun 2026filed 12 Jun 2026 | AVTX Avalo TherapeuticsBiotechnology | SEC FORM 4 Code F | $7,703588 at $13.10 | filing |
| 21 May 2026filed 26 May 2026 | AVTX Avalo TherapeuticsBiotechnology | SEC FORM 4 Code A | —34,200 at $0.00 | filing |
| 21 May 2026filed 26 May 2026 | AVTX Avalo TherapeuticsBiotechnology | SEC FORM 4 Code A | —34,200 at $0.00 | filing |
| 26 Feb 2026filed 2 Mar 2026 | AVTX Avalo Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —95,000 at $0.00 | filing |
| 26 Feb 2026filed 2 Mar 2026 | AVTX Avalo Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —95,000 at $0.00 | filing |
| 10 Dec 2025filed 12 Dec 2025 | AVTX Avalo TherapeuticsBiotechnology | SEC FORM 4 Code F | $2,612637 at $4.10 | filing |
| 1 Jan 2025filed 3 Jan 2025 | AVTX Avalo Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —150,000 at $0.00 | filing |
News
Praxis Precision Medicines (NASDAQ:PRAX) versus Avalo Therapeutics (NASDAQ:AVTX) Financial ContrastAVTX · themarketsdaily.com · 23 Oct 2026Avalo Therapeutics (NASDAQ:AVTX) Stock Rating Reaffirmed as "Neutral" by HC WainwrightAVTX · themarketsdaily.com · 23 Oct 2026Head-To-Head Survey: Avalo Therapeutics (NASDAQ:AVTX) & Ascendis Pharma A/S (NASDAQ:ASND)AVTX · themarketsdaily.com · 22 Oct 2026
0 headlines in the last 90 days name Jennifer Riley; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.